These findings unveil PLS3 as a molecular bridge linking EMT activation to immunosuppressive microenvironment remodeling in HNSCC, providing novel insights into therapeutic strategies targeting tumor cell–immune microenvironment crosstalk. This evidence concerns the gene PLS3 and neoplasm.